AbbVie Inc | ABBV.USX
United States - USD

Stock Exchange: NYSE

Symbol: ABBV

Sector: Healthcare

Industry: Drug Manufacturers - General

About AbbVie Inc

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc Stats

Previous close:Daily change:
260.21-1.44%
52-Week High:52-Week Low:
267.47190.75
Market Cap:Beta:
453.2 Billion0.28

AbbVie Inc Key Financials

P/E Ratio:Revenues:Revenue Growth:Gross Margin:
72.446364.4 Billion10.20%72.79%
Dividend Yield:Net Income:Earnings Growth:Net Income Margin:
2.70%6.3 Billion290.40%9.80%
P/E Ratio:Revenues:
72.446364.4 Billion
Dividend Yield:Net Income:
2.70%6.3 Billion
Revenue Growth:Gross Margin:
10.20%72.79%
Earnings Growth:Net Income Margin:
290.40%9.80%
ParametersStocks Investing
Stock CurrencyUSD
Dividend PayingYes
Fractional SharesYes
Maximum Shares100 Shares
Tick value per 1 share0.01 USD
Trading Commission0%
Minimum Price Increment0.01
Limit and Stop Levels0.0
Negative balance protectionNo
Swap free days allowanceN/A
Own the underlying AssetNo
Platform symbolABBV.USX
Disclaimer: 本資料は、情報提供のみを目的とした一般的なマーケティング・コミュニケーションとして第三者のデータソースから提供されたものであり、独立した投資調査を構成するものではありません。本資料には、投資助言、投資推奨、または金融商品の売買を目的とした勧誘は一切含まれておらず、また含まれているとみなされるべきでもありません。提供されるすべての情報は、信頼できる情報源から収集されたものであり、過去のパフォーマンスを示す情報は、将来のパフォーマンスを保証するものでも、信頼できる指標でもありません。利用者は、CFDおよび株式現物商品への投資は、一定の不確実性を特徴とするものであり、このような性質の投資は、利用者が単独で責任と義務を負う高度のリスクを伴うものであることを認識するものとします。当社は、ここに提示された情報に基づいて行われた投資によって生じたいかなる損失に対しても責任を負いません。